SBH
BIO icon

Segall Bryant & Hamill’s Bio-Rad Laboratories Class A BIO Stock Holding History

Segall Bryant & Hamill’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-477
Closed -$200K – 716
2022
Q4 		$200K Sell
477
-15
-3% -$6.05K ﹤0.01% 694
2022
Q3 		$204K Sell
492
-22
-4% -$11K ﹤0.01% 700
2022
Q2 		$253K Sell
514
-12
-2% -$6.25K ﹤0.01% 684
2022
Q1 		$295K Sell
526
-7,109
-93% -$4.29M ﹤0.01% 680
2021
Q4 		$5.77M Sell
7,635
-2,423
-24% -$1.81M 0.05% 308
2021
Q3 		$7.5M Sell
10,058
-2,920
-22% -$2.19M 0.07% 253
2021
Q2 		$8.36M Sell
12,978
-134
-1% -$81.6K 0.08% 239
2021
Q1 		$7.49M Buy
13,112
+1,645
+14% +$974K 0.07% 260
2020
Q4 		$6.68M Sell
11,467
-11,388
-50% -$6.49M 0.07% 244
2020
Q3 		$11.8M Buy
22,855
+2,606
+13% +$1.32M 0.16% 142
2020
Q2 		$9.14M Sell
20,249
-4,369
-18% -$1.93M 0.15% 143
2020
Q1 		$8.63M Buy
24,618
+744
+3% +$274K 0.18% 118
2019
Q4 		$8.83M Sell
23,874
-1,618
-6% -$570K 0.14% 153
2019
Q3 		$8.48M Buy
25,492
+91
+0.4% +$29.7K 0.13% 192
2019
Q2 		$7.94M Buy
25,401
+547
+2% +$164K 0.12% 208
2019
Q1 		$7.6M Sell
24,854
-358
-1% -$96.6K 0.12% 213
2018
Q4 		$5.86M Buy
25,212
+573
+2% +$154K 0.1% 241
2018
Q3 		$7.71M Sell
24,639
-1,132
-4% -$351K 0.11% 231
2018
Q2 		$7.44M Sell
25,771
-1,366
-5% -$377K 0.11% 232
2018
Q1 		$6.79M Sell
27,137
-1,787
-6% -$455K 0.16% 150
2017
Q4 		$6.9M Sell
28,924
-6,229
-18% -$1.51M 0.15% 155
2017
Q3 		$7.81M Buy
35,153
+3,790
+12% +$853K 0.18% 132
2017
Q2 		$7.1M Sell
31,363
-285
-0.9% -$62.1K 0.17% 136
2017
Q1 		$6.31M Buy
31,648
+3,000
+10% +$578K 0.15% 148
2016
Q4 		$5.22M Buy
28,648
+2,542
+10% +$433K 0.13% 166
2016
Q3 		$4.28M Buy
+26,106
New +$3.96M 0.11% 195

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Segall Bryant & Hamill's BIO Position: Q1 2023 in Review

Segall Bryant & Hamill sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2023, closing a stake of 477 shares — an estimated $200K sold.

Segall Bryant & Hamill first reported a position in BIO in Q3 2016 and held it in 26 quarters. The position peaked at $11.8M in Q3 2020. 504 funds tracked by Wall St. Rank hold BIO as of Q1 2023.

  • Segall Bryant & Hamill reported no remaining Bio-Rad Laboratories Class A position as of Q1 2023 after selling out during the quarter.
  • Segall Bryant & Hamill sold 477 Bio-Rad Laboratories Class A shares in Q1 2023, an estimated $200K.
  • Segall Bryant & Hamill first reported a position in Bio-Rad Laboratories Class A in Q3 2016 and held it in 26 quarters.
  • Segall Bryant & Hamill's Bio-Rad Laboratories Class A position peaked at $11.8M in Q3 2020.
  • 504 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2023.

Based on Segall Bryant & Hamill's 13F filing for Q1 2023, filed 15 May 2023.